BidaskClub cut shares of NuVasive (NASDAQ:NUVA) from a strong-buy rating to a buy rating in a report issued on Friday morning.
Several other brokerages have also recently commented on NUVA. ValuEngine raised NuVasive from a hold rating to a buy rating in a research report on Wednesday, September 19th. Canaccord Genuity increased their price target on NuVasive from $70.00 to $80.00 and gave the company a buy rating in a research report on Tuesday, September 18th. Zacks Investment Research raised NuVasive from a sell rating to a hold rating in a research report on Tuesday, August 21st. Cowen increased their price target on NuVasive from $62.00 to $80.00 and gave the company an outperform rating in a research report on Tuesday, September 11th. They noted that the move was a valuation call. Finally, BTIG Research increased their price target on NuVasive to $72.00 and gave the company a buy rating in a research report on Thursday, August 16th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the stock. NuVasive presently has a consensus rating of Hold and an average target price of $65.53.
Shares of NASDAQ NUVA opened at $68.40 on Friday. NuVasive has a 52 week low of $44.62 and a 52 week high of $72.12. The company has a market cap of $3.54 billion, a P/E ratio of 35.81, a P/E/G ratio of 1.89 and a beta of 0.68.
A number of large investors have recently added to or reduced their stakes in NUVA. Rockefeller Capital Management L.P. bought a new stake in NuVasive in the first quarter valued at approximately $141,000. Strs Ohio raised its stake in NuVasive by 45.5% in the second quarter. Strs Ohio now owns 3,200 shares of the medical device company’s stock valued at $166,000 after buying an additional 1,000 shares during the period. Sun Life Financial INC bought a new stake in NuVasive in the second quarter valued at approximately $201,000. Cubist Systematic Strategies LLC bought a new position in shares of NuVasive during the second quarter worth approximately $221,000. Finally, Hartford Investment Management Co. bought a new position in shares of NuVasive during the second quarter worth approximately $245,000.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Story: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.